Abstract
Until recently, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3)—the active form of vitamin D—was thought to function primarily as a regulator of calcium and phosphate metabolism. More diverse functionality was indicated by the discovery of the vitamin D receptor in tissues that are not involved in calcium and phosphate homeostasis. Detection of the vitamin D receptor in monocytes and activated T cells has sparked interest in the immunomodulatory properties of vitamin D. Here, we review the role of vitamin D in regulation of the immune system, and evidence for its involvement in the pathogenesis of inflammatory bowel disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Holick MF (1994) McCollum Award Lecture, 1994: vitamin D—new horizons for the 21st century. Am J Clin Nutr 60: 619–630
Haussler MR et al. (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13: 325–349
Sutton AL and MacDonald PN (2003) Vitamin D: more than a “bone-a-fide” hormone. Mol Endocrinol 17: 777–791
Zittermann A (2003) Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 89: 552–572
Li YC et al. (2002) 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110: 229–238
Endo I et al. (2003) Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology 144: 5138–5144
Zinser G et al. (2002) Vitamin D(3) receptor ablation alters mammary gland morphogenesis. Development 129: 3067–3076
Nagpal S et al. Non-calcemic action of vitamin D receptor ligands. Endocrine Rev, in press
Holick MF (2003) Vitamin D: A millenium perspective. J Cell Biochem 88: 296–307
Bhalla AK et al. (1983) Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab 57: 1308–1310
Provvedini DM et al. (1983) 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 221: 1181–1183
Manolagas SC et al. (1986) The antiproliferative effect of calcitriol on human peripheral blood mononuclear cells. J Clin Endocrinol Metab 63: 394–400
Brennan A et al. (1987) Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D3 metabolite, dihydroxycholecalciferol. Immunology 61: 457–461
Veldman CM et al. (2000) Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 374: 334–338
Rigby WF et al. (1984) Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). J Clin Invest 74: 1451–1455
Bhalla AK et al. (1984) 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol 133: 1748–1754
Stio M et al. (2001) Suppressive effect of 1,25-dihydroxyvitamin D3 and its analogues EB 1089 and KH 1060 on T lymphocyte proliferation in active ulcerative colitis. Biochem Pharmacol 61: 365–371
Stio M et al. (2002) Synergistic inhibitory effect of cyclosporin A and vitamin D derivatives on T-lymphocyte proliferation in active ulcerative colitis. Am J Gastroenterol 97: 679–689
Rigby WF et al. (1987) Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J Clin Invest 79: 1659–1664
Lemire JM (1992) Immunomodulatory role of 1,25-dihydroxyvitamin D3. J Cell Biochem 49: 26–31
Alroy I et al. (1995) Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol 15: 5789–5799
Cippitelli M and Santoni A (1998) Vitamin D3: a transcriptional modulator of the interferon-gamma gene. Eur J Immunol 28: 3017–3030
Boonstra A et al. (2001) 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 167: 4974–4980
Mahon BD et al. (2003) The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem 89: 922–932
Nashold FE et al. (2001) Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D(3) prevention of experimental autoimmune encephalomyelitis. J Neuroimmunol 119: 16–29
Mattner F et al. (2000) Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3). Eur J Immunol 30: 498–508
D'Ambrosio D et al. (1998) Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 101: 252–262
Penna G and Adorini L (2000) 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164: 2405–2411
Piemonti L et al. (2000) Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 164: 4443–4551
Berer A et al. (2000) 1,25-Dihydroxyvitamin D(3) inhibits dendritic cell differentiation and maturation in vitro. Exp Hematol 28: 575–583
Canning MO et al. (2001) 1-alpha,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur J Endocrinol 145: 351–357
Gregori S et al. (2001) Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 167: 1945–1953
Barrat FJ et al. (2002) In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 195: 603–616
Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347: 417–429
Loftus EV Jr and Sandborn WJ (2002) Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 31: 1–20
Loftus EV Jr (2004) Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 126: 1504–1517
Sellu DP (1986) Seasonal variation in onset of exacerbations of ulcerative proctocolitis. J R Coll Surg Edinb 31: 158–160
Moum B et al. (1996) Seasonal variations in the onset of ulcerative colitis. Gut 38: 376–378
Zeng L and Anderson FH (1996) Seasonal change in the exacerbations of Crohn's disease. Scand J Gastroenterol 31: 79–82
Webb AR et al. (1988) Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 67: 373–378
Vogelsang H et al. (1989) Bone disease in vitamin D-deficient patients with Crohn's disease. Dig Dis Sci 34: 1094–1099
Holick MF (2002) Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health. Curr Opin Endocrinol Diabetes 9: 87–98
Probert CS et al. (1990) Inflammatory bowel disease in the rural Indian subcontinent: a survey of patients attending mission hospitals. Digestion 47: 42–46
Probert CS et al. (1992) Epidemiological study of ulcerative proctocolitis in Indian migrants and the indigenous population of Leicestershire. Gut 33: 687–693
Carr I and Mayberry JF (1999) The effects of migration on ulcerative colitis: a three-year prospective study among Europeans and first- and second-generation South Asians in Leicester (1991-1994). Am J Gastroenterol 94: 2918–2922
Driscoll RH Jr et al. (1982) Vitamin D deficiency and bone disease in patients with Crohn's disease. Gastroenterology 83: 1252–1258
Harries AD et al. (1985) Vitamin D status in Crohn's disease: association with nutrition and disease activity. Gut 26: 1197–1203
Andreassen H et al. (1998) Regulators of calcium homeostasis and bone mineral density in patients with Crohn's disease. Scand J Gastroenterol 33: 1087–1093
Abitbol V et al. (1995) Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 108: 417–422
Bernstein CN et al. (1995) Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 10: 250–256
Abreu MT et al. (2004) Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut 53: 1129–1136
Bernstein CN et al. (2003) AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 124: 795–841
Schoon EJ et al. (2000) Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 119: 1203–1208
Lee SH et al. (2000) Decreased trabecular bone mineral density in newly diagnosed inflammatory bowel disease patients in Korea. J Gastroenterol Hepatol 15: 512–518
Lamb EJ et al. (2002) Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 16: 1895–902
Malabanan A et al. (1998) Redefining vitamin D insufficiency. Lancet 351: 805–806
Chapuy MC et al. (1997) Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 7: 439–443
Kuhn R et al. (1991) Generation and analysis of interleukin-4 deficient mice. Science 254: 707–710
Kuhn R et al. (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263–274
MacDonald TT (1994) Gastrointestinal inflammation. Inflammatory bowel disease in knockout mice. Curr Biol 4: 261–263
Cantorna MT et al. (2000) 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 130: 2648–2652
Aranda R et al. (1997) Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients. J Immunol 158: 3464–3473
Morrissey PJ et al. (1993) CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J Exp Med 178: 237–244
Froicu M et al. (2003) A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol 17: 2386–2392
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Glossary
- CD28
-
A T-cell surface molecule and the CD80/CD86 receptor; binding of CD80/CD86 to CD28 is involved in T-cell activation and the initiation and maintenance of chronic inflammation
- CD154 (CD40L)
-
A membrane glycoprotein expressed on T cells; interaction of CD40 with CD154 is important in T-cell activation, T-cell–B-cell crosstalk, B-cell proliferation and differentiation, and memory cell formation
- CD80
-
A cell-surface molecule expressed by monocytes, macrophages, dendritic cells and activated B cells; it binds CD28 and CD152 (important for T-cell co-stimulation and activation, T-cell–B-cell crosstalk, and antibody production)
- CD86
-
A cell-surface molecule expressed at low levels on activated B cells, monocytes, and macrophages, and at high levels on dendritic cells; it binds CD28 and CD152 (important for T-cell co-stimulation and activation, T-cell–B-cell crosstalk, and antibody production)
- CD40
-
A membrane glycoprotein expressed on dendritic cells, monocytes, B cells, and T cells; important in inflammatory pathways (IL-12 production, polarization towards the Th1 type, CD8+ T-cell proliferation, NK cell activation) and B-cell functions
- MYCOPHENOLATE MOFETIL
-
An immunosuppressive drug approved for use in certain organ transplant patients to prevent organ rejection
- LEVEL B EVIDENCE
-
Nonrandomized clinical trials, nonquantitative systematic reviews, clinical cohort and case-controlled studies, high-quality historical uncontrolled studies, and epidemiologic studies
- OSTEOMALACIA
-
Softening or decreased mineralization of the bones caused by a vitamin D deficiency or problems with vitamin D metabolism
Rights and permissions
About this article
Cite this article
Lim, WC., Hanauer, S. & Li, Y. Mechanisms of Disease: vitamin D and inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2, 308–315 (2005). https://doi.org/10.1038/ncpgasthep0215
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep0215
This article is cited by
-
The Role of Vitamin D in Health and Disease: A Narrative Review on the Mechanisms Linking Vitamin D with Disease and the Effects of Supplementation
Drugs (2023)
-
Vitamin D receptor upregulates tight junction protein claudin-5 against colitis-associated tumorigenesis
Mucosal Immunology (2022)
-
Growth, puberty, and bone health in children and adolescents with inflammatory bowel disease
BMC Pediatrics (2021)
-
RNF20 and RNF40 regulate vitamin D receptor-dependent signaling in inflammatory bowel disease
Cell Death & Differentiation (2021)
-
Vitamin D Deficiency Exacerbates Colonic Inflammation Due to Activation of the Local Renin–Angiotensin System in the Colon
Digestive Diseases and Sciences (2021)